The ablation catheter integrates a precision sensor near its tip that measures the force applied to cardiac tissue during the procedure. This contact force data is displayed in real time, enabling physicians to assess catheter-to-tissue interaction more effectively. According to Johnson & Johnson, this capability is intended to help electrophysiologists optimize lesion formation while performing ablation for atrial fibrillation and other arrhythmias. The THERMOCOOL SMARTTOUCH catheter is compatible with the company’s CARTO 3 System, which is widely used in electrophysiology labs for three-dimensional cardiac mapping.

Biosense Webster developed the force-sensing technology to address variability in catheter contact during ablation procedures. Inconsistent contact force has been identified in clinical literature as a factor that may affect procedural outcomes. By equipping physicians with direct feedback on the force being applied, the device aims to improve consistency across procedures. The THERMOCOOL SMARTTOUCH catheter builds upon the established THERMOCOOL platform, which has been used extensively in ablation catheter procedures worldwide.

The European launch positions Johnson & Johnson to compete in the growing market for advanced electrophysiology devices. Atrial fibrillation remains one of the most common cardiac arrhythmias globally, and demand for catheter-based treatments continues to rise. With the THERMOCOOL SMARTTOUCH catheter now available in Europe, Biosense Webster expands its portfolio of ablation catheter technologies equipped with real-time sensing capabilities. The company has stated that clinical data supporting the device’s performance will continue to be gathered as adoption increases across European electrophysiology centers.

The framework has received support from healthcare policy specialists and stakeholders within the medtech sector, who believe it could help NHS purchasing decisions better account for the long-term benefits and impact of healthcare technologies. Chris Whitehouse, Director of Health and MedTech Policy at Whitehouse Communications, which advises medical device suppliers, said: “For many years, procurement decisions across parts of the NHS have too often been driven primarily by upfront cost.” While the framework establishes a new direction for procurement practices, industry observers note that its success will depend on how effectively it is adopted across NHS organisations and integrated into existing decision-making processes.

Attention will also be required in areas such as procurement culture and stakeholder engagement to ensure the intended benefits are realised. Whitehouse emphasised that policy changes alone would not be enough to transform purchasing practices, stating: “Changing procurement frameworks on paper is relatively straightforward. Changing behaviours and cultures that have developed over many years is much harder,” he said. A central feature of the framework is the earlier involvement of clinicians in procurement discussions, recognising their insight into how technologies perform in real-world healthcare environments and how they influence patient care.

The framework further underlines the importance of patient experience as a measure of value. NHS organisations are encouraged to consider how technologies affect factors such as independence, dignity and quality of life when assessing procurement options. Through this outcomes-focused model, value-based procurement for Medical Device assessment aims to support more informed purchasing decisions while aligning procurement practices with broader healthcare objectives across the NHS.

The transition to microfactories revolutionizing medical device production represents a significant departure from the “one-size-fits-all” approach that has dominated the industry for decades. In a centralized system, a manufacturer might produce millions of identical orthopedic implants, which are then shipped globally and stored in expensive inventories. However, every patient’s anatomy is different, and a standard implant may not always provide the optimal fit. Microfactories solve this problem by allowing clinicians to send patient-specific data such as a CT scan of a fractured bone directly to a localized manufacturing unit. Within hours, the microfactory can produce a custom implant that fits the patient’s bone structure perfectly, leading to better surgical outcomes, faster recovery times, and a reduced risk of complications.

The Technological Core of Localized Manufacturing

The feasibility of microfactories revolutionizing medical device production is built upon the pillars of Industry 4.0. At the heart of these units is additive manufacturing (3D printing), which allows for the creation of complex geometries that are impossible to achieve through traditional machining or molding. Whether it is a titanium hip replacement with a lattice structure that promotes bone ingrowth or a patient-specific surgical guide for a complex spinal procedure, 3D printing provides the flexibility needed for high-value, low-volume production. This capability is essential for localized manufacturing, where the goal is not to produce millions of items, but to produce the right item for the right patient at the right time.

Beyond 3D printing, microfactories revolutionizing medical device production integrate sophisticated robotics and automated quality control systems. Because these units are often operated by a smaller workforce or even autonomously, the reliance on smart manufacturing healthcare technology is paramount. High-resolution cameras and AI-driven inspection algorithms can monitor the manufacturing process in real-time, ensuring that every layer of a printed part meets the rigorous safety standards required for medical use. This level of automated validation is critical for maintaining the integrity of the medical device manufacturing process outside of a traditional factory setting. By digitizing the quality assurance pipeline, microfactories can achieve a level of precision and consistency that matches, and often exceeds, that of large-scale industrial facilities.

Strengthening the Global Medical Supply Chain

The COVID-19 pandemic exposed the profound vulnerabilities of the global medical supply chain, as hospitals struggled to secure essential items due to factory closures and logistics breakdowns. Microfactories revolutionizing medical device production offer a powerful solution to this problem by creating a decentralized network of manufacturing hubs. Instead of relying on a single factory in a distant country, a health system can have multiple microfactories spread across different regions. This decentralization ensures that if one part of the supply chain is disrupted, others can continue to function, providing a high degree of resilience for the healthcare infrastructure.

Localized manufacturing also has significant environmental benefits. By producing devices close to the point of use, microfactories drastically reduce the carbon footprint associated with long-distance shipping and air freight. Furthermore, because these units produce items on-demand, there is far less need for massive warehouses full of inventory that might expire or become obsolete before it is ever used. This reduction in waste aligns with the broader movement toward sustainable healthcare, making microfactories revolutionizing medical device production a key component of the “green” medical supply chain of the future. The ability to create what is needed, when it is needed, is the ultimate expression of efficiency in a world with finite resources.

Accelerating Innovation and Personalized Care

One of the most exciting aspects of microfactories revolutionizing medical device production is the acceleration of the innovation cycle. In the traditional model, bringing a new medical device to market is a slow and expensive process, often taking years of development and testing. Microfactories allow for rapid prototyping and iterative design, enabling researchers and clinicians to test new ideas and refine their designs in a fraction of the time. This “fast-track” to innovation is particularly beneficial for the development of niche medical devices, such as pediatric implants or tools for rare surgical procedures, which are often ignored by large manufacturers due to their small market size.

Personalized care is the ultimate goal of modern medicine, and microfactories are the tools that make it a reality. Beyond implants, these units can be used to produce personalized drug delivery systems, custom prosthetics, and even bio-printed tissues. The ability to “print” a prosthetic limb that is perfectly matched to a child’s growth pattern, or a medication patch that releases a specific dose of drugs tailored to a patient’s metabolism, is no longer science fiction. Microfactories revolutionizing medical device production are providing the infrastructure needed to scale these breakthroughs, moving them from the lab to the bedside. This democratized access to high-end medical technology has the potential to level the playing field, ensuring that the benefits of personalized medicine are available to patients regardless of their geographic location.

Navigating Regulatory and Quality Challenges

While the promise of microfactories revolutionizing medical device production is immense, their widespread adoption requires a new approach to regulation. Regulatory bodies like the FDA have traditionally focused on “factory-based” oversight, where the manufacturing process is validated in a single location. Localized manufacturing, however, shifts the production to many different sites. This requires a transition to “process-based” regulation, where the digital files, the equipment specifications, and the automated quality control systems are certified, rather than the physical location itself. Ensuring that a device produced in a microfactory in London is identical in quality to one produced in a microfactory in New York is a significant challenge that requires global collaboration on data standards and validation protocols.

Cybersecurity is another critical consideration for microfactories revolutionizing medical device production. As manufacturing becomes increasingly digital, the risk of “IP theft” or the malicious alteration of a device design becomes a real threat. Protecting the digital blueprint of a patient-specific implant as it is transmitted from the hospital to the microfactory is essential for patient safety. This requires the implementation of robust encryption, blockchain-based tracking, and secure cloud environments. By addressing these security and regulatory hurdles, the medical device industry can build the trust needed to fully embrace the decentralized manufacturing revolution.

Conclusion: The Dawn of Distributed Medical Manufacturing

The rise of microfactories revolutionizing medical device production marks the beginning of a new chapter in the history of medical technology. It is a shift from a world of rigid, centralized production to a future of agile, localized, and personalized manufacturing. By bringing the “factory” to the patient, we are not just improving the efficiency of the supply chain we are fundamentally changing the nature of the relationship between technology and care.

As we look forward, the impact of these mini-factories will only continue to grow. They will become integrated into the fabric of the hospital, working alongside clinicians to solve complex medical challenges in real-time. They will empower surgeons with better tools, provide patients with better outcomes, and create a more resilient and sustainable healthcare system for everyone. Microfactories are not just a new way to make things they are a new way to heal, ensuring that the next generation of medical innovation is as unique as the patients it serves. The revolution has begun, and the microfactory is at its center, building a healthier world one personalized device at a time.

The urgency of this transition cannot be overstated. If the global healthcare sector were a country, it would be the fifth-largest emitter of greenhouse gases on earth. A significant portion of this environmental footprint is tied to the supply chain and the production of medical consumables. Sustainable medical devices supporting green hospitals address this challenge by introducing “circular economy” principles into the clinical setting. This involves moving away from the “take-make-dispose” model and toward a system where devices are designed for reuse, remanufacturing, and recycling. As hospitals around the world commit to net-zero targets, the demand for eco-friendly medical devices is skyrocketing, forcing manufacturers to innovate at a rapid pace.

Redesigning the Lifecycle of Medical Equipment

The first step in the creation of sustainable medical devices supporting green hospitals is the selection of materials. Traditionally, medical-grade plastics are chosen for their durability and sterility, but many of these materials are non-recyclable and can leach harmful chemicals when incinerated. Modern innovation is focusing on bio-based polymers and high-quality plastics that can withstand multiple sterilization cycles without losing their structural integrity. By designing products that are inherently durable, manufacturers can transition many items from single-use to multi-use categories, drastically reducing the volume of waste generated by a single surgical procedure.

Moreover, the manufacturing process itself is being overhauled to support healthcare sustainability. Sustainable medical devices supporting green hospitals are increasingly produced in facilities powered by renewable energy, utilizing additive manufacturing (3D printing) to reduce material waste during production. 3D printing allows for the precise creation of components, using only the exact amount of material needed, which is a stark contrast to traditional subtractive manufacturing methods. Additionally, localized manufacturing reduces the carbon footprint associated with long-distance shipping and complex global supply chains, ensuring that hospitals have access to the equipment they need without the heavy environmental cost of transportation.

The Role of Remanufacturing in Medical Waste Reduction

Remanufacturing is a cornerstone of the strategy for sustainable medical devices supporting green hospitals. Many high-value medical devices, such as electrophysiology catheters and ultrasonic scalpels, have traditionally been discarded after a single use due to safety concerns. However, advanced remanufacturing processes now allow these devices to be collected, cleaned, tested, and sterilized back to their original performance specifications. These remanufactured devices are often indistinguishable from “new” products in terms of safety and efficacy but cost significantly less and have a much lower environmental impact.

By adopting remanufactured sustainable medical devices supporting green hospitals, facilities can achieve substantial cost savings while meeting their medical waste reduction goals. This practice is supported by increasingly rigorous regulatory frameworks that ensure remanufactured devices meet the same quality standards as original equipment. For hospital administrators, this creates a win-win scenario: they can reduce their operational expenses and their environmental footprint without compromising on the quality of the tools available to their surgeons. This circular approach to equipment management is essential for the long-term viability of green hospitals, particularly as the cost of waste disposal continues to rise.

Eco-Friendly Innovations in Packaging and Distribution

Sustainability in the medical device sector also extends to the “outer layers” of the product the packaging and distribution. A significant portion of hospital waste is composed of the cardboard, plastic film, and foam used to transport and protect medical equipment. Sustainable medical devices supporting green hospitals are now being delivered in minimal, recyclable, or even compostable packaging. Manufacturers are working to optimize packaging sizes to reduce shipping volume, which in turn reduces the number of delivery vehicles needed and the associated fuel consumption.

Digitalization is also playing a role in reducing the environmental impact of distribution. By using smart inventory management systems, hospitals can ensure they are not over-ordering supplies, which often leads to items expiring before they are used and eventually being thrown away. These “just-in-time” systems, combined with real-time tracking of device usage, allow for a more streamlined and less wasteful supply chain. This level of precision is a key component of hospital sustainability, ensuring that resources are used as efficiently as possible and that the “green” in green hospitals refers to both environmental and financial health.

Collaborative Strategies for Global Healthcare Sustainability

Achieving the widespread adoption of sustainable medical devices supporting green hospitals requires a collaborative effort across the entire healthcare ecosystem. Clinicians must be involved in the design and testing of new products to ensure that eco-friendly alternatives meet their practical needs in the operating room. Procurement teams need to shift their focus from the lowest initial price to the “total cost of ownership,” which includes the environmental costs of disposal and the potential savings from reuse. Policy makers and regulators also have a role to play by providing incentives for the development of sustainable technology and setting clear standards for environmental reporting in healthcare.

On a global scale, the movement toward sustainable medical devices supporting green hospitals is helping to address the healthcare needs of underserved populations. In many parts of the world, the high cost of single-use medical equipment is a barrier to providing quality care. By developing durable, reusable, and locally repairable medical devices, manufacturers can provide more affordable solutions that are better suited to the resource constraints of low- and middle-income countries. This intersection of environmental sustainability and global health equity is one of the most powerful arguments for the continued innovation of green medical technology.

Conclusion: Building a Healthier Planet through Better Technology

The transition toward sustainable medical devices supporting green hospitals is more than just an environmental initiative it is a professional evolution of the medical device industry. It represents an acknowledgement that the health of the individual cannot be separated from the health of the environment. As we continue to face the challenges of climate change and resource scarcity, the healthcare sector must lead by example, demonstrating that innovation and responsibility can go hand in hand.

By choosing sustainable medical devices supporting green hospitals, healthcare systems are making a long-term investment in the future of our planet. The reduction in waste, the improvement in resource efficiency, and the advancement of circular economy principles are all steps toward a more resilient and compassionate healthcare system. As more hospitals join the green movement and more manufacturers embrace sustainable design, the “green hospital” will move from a visionary concept to a global standard, ensuring that the technology we use to heal does not inadvertently harm the world we live in.

The move toward smart sterilization systems enhancing patient safety represents a strategic shift from passive equipment management to active, data-driven oversight. In a traditional setup, once an instrument tray enters an autoclave, its status is largely a black box until the cycle completes. If a sensor fails or a temperature fluctuation occurs unnoticed, the risk of a non-sterile instrument reaching the operating theater becomes a terrifying possibility. Smart systems eliminate this uncertainty by providing continuous monitoring of critical parameters such as pressure, temperature, and chemical concentrations directly to a centralized dashboard. This level of transparency not only ensures immediate intervention in the event of a cycle failure but also creates a permanent, unalterable digital twin of every sterilization event, providing a level of accountability and compliance that manual logs simply cannot match.

Integrating CSSD Technology into the Modern Clinical Workflow

The Central Sterile Supply Department is often described as the heart of the hospital, pumping clean resources into every clinical artery. When smart sterilization systems enhancing patient safety are integrated into this environment, the efficiency of the entire hospital improves. Advanced CSSD technology utilizes Radio Frequency Identification (RFID) and 2D barcodes to track individual instruments through their entire lifecycle from the point of use in the operating room to decontamination, assembly, sterilization, and storage. This granular visibility allows hospital administrators to optimize instrument utilization, reducing the need for costly “just-in-case” inventory and ensuring that high-demand surgical kits are processed with maximum throughput.

Beyond logistics, the human element of sterilization is greatly supported by these automated systems. Sterilization technicians operate under immense pressure, often managing thousands of unique instruments every day. Smart sterilization systems enhancing patient safety reduce the cognitive load on these essential workers by providing guided workflows and automated verification steps. For example, an intelligent workstation can scan a surgical tray and immediately alert the technician if a single component is missing or if an instrument is nearing its maintenance threshold. This preventative approach to equipment management not only safeguards the patient but also extends the lifespan of expensive medical assets, contributing to the overall financial health of the institution.

The Critical Role of Infection Prevention and Compliance

Infection prevention is the primary driver behind the adoption of smart sterilization systems enhancing patient safety. Healthcare-associated infections are not merely a clinical failure; they are a significant financial burden on the healthcare system, leading to extended hospital stays and increased litigation risks. By ensuring a higher degree of sterilization reliability, smart systems act as a critical line of defense against multidrug-resistant organisms (MDROs) and other pathogens that thrive in clinical environments. The ability to correlate a specific sterilization cycle with a specific patient outcome allows for unprecedented “trace-back” capabilities. If an infection occurs, the hospital can quickly verify the sterilization history of the instruments used, either ruling out the equipment as a source or identifying a systemic failure that needs immediate correction.

Compliance with international standards, such as those set by the Joint Commission or ISO, is another area where smart sterilization systems enhancing patient safety provide immense value. Regulatory audits often require the retrieval of months or years of sterilization records. In a manual system, this is a labor-intensive process prone to missing documentation. Digital systems, however, generate comprehensive compliance reports at the touch of a button. These reports include every parameter of the sterilization cycle, the identity of the technician who processed the load, and the biological indicator results. This readiness for inspection reduces the administrative burden on hospital staff and ensures that the facility consistently meets the highest safety benchmarks.

Enhancing Medical Equipment Sterilization through IoT and AI

The future of medical equipment sterilization is deeply intertwined with the evolution of artificial intelligence and machine learning. As smart sterilization systems enhancing patient safety collect more data over time, they can begin to perform predictive analytics. For instance, the system might notice that a particular autoclave is starting to take longer to reach its target temperature, signaling a potential heater failure before it actually occurs. This transition from reactive to predictive maintenance ensures that the CSSD experiences minimal downtime, preventing the “surgical gridlock” that occurs when sterile supplies run low.

Furthermore, AI can assist in the optimization of sterilization recipes. Different materials from traditional stainless steel to modern polymers used in robotic surgery require different sterilization parameters to ensure both sterility and material integrity. Smart sterilization systems enhancing patient safety can automatically recognize the composition of a tray and adjust the cycle accordingly. This level of precision is particularly important as surgical technology becomes more complex. Robotic surgical instruments, for example, have narrow lumens and delicate components that are difficult to clean and can be easily damaged by traditional high-heat methods. Intelligent low-temperature sterilization systems are being developed specifically to handle these high-value assets, ensuring they are safe for the next patient without compromising their functionality.

Scaling Patient Safety Across Global Healthcare Facilities

The implementation of smart sterilization systems enhancing patient safety is not a luxury reserved for elite academic centers; it is a global necessity. In developing regions, where the burden of infectious disease is often higher and resources are more constrained, the efficiency gains provided by smart technology can be transformative. While the initial capital investment may be higher than traditional equipment, the long-term savings in terms of reduced infection rates and improved asset management provide a compelling return on investment. Furthermore, the ability to monitor these systems remotely allows for expert oversight of sterilization practices in rural or underserved areas, bridging the gap in clinical expertise.

As we look toward the next decade of healthcare innovation, the focus will increasingly be on the “connected hospital.” In this vision, smart sterilization systems enhancing patient safety do not exist in isolation. They will be seamlessly connected to the electronic health record (EHR) and the operating room management software. This connectivity will allow for real-time adjustments to the surgical schedule based on the availability of sterile supplies. If an emergency surgery requires a specific set of instruments, the system can automatically prioritize those items in the sterilization queue, ensuring that the clinical team has what they need exactly when they need it.

Conclusion: A New Benchmark for Hospital Sterilization

The journey toward a zero-infection surgical environment is a challenging one, but smart sterilization systems enhancing patient safety are making it a reachable goal. By replacing manual uncertainty with digital precision, these systems are raising the bar for what we expect from hospital hygiene. They protect the most vulnerable patients, support the most hardworking staff, and ensure that the promise of modern surgery is never undermined by a failure in the most basic of clinical requirements: cleanliness. As technology continues to advance, the “smart” in sterilization will no longer be an optional upgrade, but the foundational standard upon which all patient safety is built.

The adoption of these systems is a testament to the healthcare industry’s commitment to continuous improvement. By embracing the power of data and automation, hospitals are not just cleaning tools; they are building a culture of safety that extends into every corner of the facility. The peace of mind that comes from knowing every instrument is validated and safe is invaluable to surgeons, nurses, and, most importantly, the patients who trust their lives to the medical community. In the end, smart sterilization systems enhancing patient safety represent the perfect harmony of technology and care, ensuring that the future of surgery is as safe as it is innovative.

The Thunderbolt platform broadens Penumbra’s existing CAVT portfolio and is engineered to detect, fatigue and completely ingest clot during procedures. According to the company, the technology represents an advancement in acute ischemic stroke care and is powered by its Engine platform. With the European authorization, Penumbra said the device becomes the first and only CAVT technology available for stroke treatment in both the U.S. and Europe. The Thunderbolt Thrombectomy system will be supplied pre-packaged with one of the company’s catheter options, including Red 62, Red 68, Red 72, Silver Label or Red 72 Silver Label with SENDit technology.

The Alameda, California-based company described the approval as a significant milestone for its neurovascular business. Penumbra noted that the technology builds on two decades of research and development focused on clot-treatment solutions. The company also stated that it remains the only provider offering CAVT technology across both vascular and neurovascular care applications.

Commenting on the approval, Shruthi Narayan, president of Penumbra, said: “Thunderbolt is a culmination of two decades of research and innovation at Penumbra. By introducing CAVT to the neurovascular field in Europe, we are ushering in a new era of stroke management that will have a significant impact on patient care. We are the only company to offer CAVT technology across both vascular and neurovascular care as we are committed to transforming how life-threatening clots are treated from head-to-toe worldwide.”

Joan Kristensen, head of EMEA for Penumbra, added: “Thunderbolt has the potential to shorten procedure times improving patient safety, delivering better outcomes and streamlining care for the physicians who treat them. Bringing this technology to Europe is a significant milestone and a reflection of Penumbra’s ongoing commitment to putting the most advanced stroke care tools in the hands of physicians across the region.”

Commenting on the milestone, Medtronic ENT business president Sean Haag said: “Receiving the CE mark for the Stealth AXiS surgical system in ENT procedures is an important milestone for ENT surgeons and patients across Europe. “This platform builds on our long legacy in surgical navigation while introducing a more connected, intelligent system specifically designed for the future of ENT surgery.” The Stealth AXiS ENT Platform supports a range of procedures, including minimally invasive sinus surgery, skull base interventions and sinus balloon treatments. It is also integrated with Medtronic’s AiBLE ENT smart ecosystem, which links technologies and helps optimise workflow across ENT surgical settings.

Medtronic ENT business international vice-president Panos Drakoulas said: “We’re excited to reach this milestone and expand access to the Stealth AXi surgical system across Europe. “ENT surgeons are looking for technology that fits naturally into their workflow while helping them navigate basic to highly complex anatomy with confidence. “The Stealth AXiS surgical system was built with those insights in mind, and we look forward to supporting more surgeons and patients across the region.” The European approval follows US Food and Drug Administration (FDA) clearance for ENT applications earlier this year. The system has also received CE marking for spinal and cranial procedures. In May 2026, Medtronic also secured CE mark approval for its VitalFlow Transport Frame Air and Ground accessory, which is used with the VitalFlow extracorporeal membrane oxygenation system.

Among the newly cleared capabilities is Auto Measure Abdomen, an AI-enabled feature developed to automate routine measurement tasks during examinations. Philips said the technology can help reduce variability in measurements while saving time for clinicians. The company also expanded access to Koios AI decision-support tools, which were previously available off-cart. The functionality is now integrated directly into EPIQ Elite and Affiniti systems, allowing clinicians to classify breast lesions and thyroid nodules within the ultrasound workflow. According to Philips, integration with Koios Bi-RADS enables interpretation and malignancy risk assessment in less than two seconds.

The Elevate Plus package also introduces imaging upgrades aimed at improving visualization of anatomy and blood flow. Philips said XRes Pro+ provides cleaner tissue detail and sharper anatomical boundaries, helping create more consistent images across different body types. In addition, Super Res MVI Pro enhances visualization of microvascular flow, giving clinicians greater clarity when assessing blood circulation and vascular structures. These enhancements are designed to improve image quality while supporting more efficient diagnostic workflows.

Commenting on the clearance, Jie Xue, chief business leader, Precision Diagnosis, Philips, said: “Elevate Plus underscores our commitment to advancing AI-powered ultrasound to help clinicians deliver more consistent, efficient, and confident ultrasound care to patients. By combining intelligent imaging with AI-powered workflow automation across our ultrasound platform, Elevate Plus is designed to reduce variability, streamline routine exams, and support faster, more informed clinical decisions as care teams face growing demand.”

Gretchen Sammy, ultrasound manager at Boston Medical Center, stated: “Elevate Plus is a game-changer for our ultrasound workflow. Automating key measurement tasks allows our sonographers to reduce scanning time by up to 30% without sacrificing clinical precision. During our evaluation, measurements were consistently placed exactly where we would expect them saving time while maintaining the accuracy we rely on.”

Maria Cristina Chammas, director of ultrasound at Hospital das Clínicas, School of Medicine, University of São Paulo, added that AI Ultrasound automation could help shorten scanning times, improve workflow efficiency and reduce repetitive manual tasks that contribute to sonographer fatigue while supporting more consistent clinical results.

The updated LEAF Platform features a redesigned wearable sensor that is smaller, more comfortable, and easier for patients to use at home. The system enables care teams to remotely monitor patient progress by collecting data on physical activity and rehabilitation adherence during the recovery period. The platform is intended to give clinicians meaningful, real-time visibility into how patients are recovering after procedures such as total knee and total hip replacements.

According to Smith+Nephew, the next-generation system includes improvements in sensor design and connectivity, making it more practical for widespread clinical use. The company indicated that the LEAF Platform is part of its broader digital and robotics strategy, which is focused on delivering connected care solutions that bridge the gap between surgical procedures and long-term patient outcomes. Remote patient monitoring through wearable sensor technology has increasingly become a priority for healthcare providers seeking to manage patient recovery more efficiently while reducing unnecessary clinical visits.

Smith+Nephew stated that the LEAF Platform launch aligns with growing demand among healthcare systems for scalable digital tools that extend the reach of clinical care teams. The platform is designed to integrate into existing care workflows, allowing providers to act on recovery data without disrupting established protocols. With the next-generation LEAF Platform now available, Smith+Nephew reinforces its position in the expanding remote patient monitoring market, where wearable sensor adoption continues to gain traction across orthopaedic and rehabilitation settings.

Noctrix Health had developed a wearable neurostimulation device designed to treat moderate-to-severe restless legs syndrome through its proprietary TOMAC therapy, which works by delivering targeted electrical stimulation to the legs. The therapy represents a non-pharmacological treatment pathway for RLS, an area where treatment options have historically been limited and where patients often face challenges with long-term medication adherence or side effects. The acquisition of Noctrix Health is structured as an upfront payment combined with additional milestone-based consideration, with the total deal reaching up to $340 million depending on the achievement of certain commercial and regulatory milestones.

ResMed’s Chief Executive Officer Mick Farrell highlighted the strategic importance of the transaction, describing Noctrix Health’s TOMAC therapy as a meaningful addition to the company’s growing portfolio of sleep health solutions. ResMed, which is widely known for its continuous positive airway pressure (CPAP) devices and software solutions for sleep apnea management, has been actively broadening its reach across various sleep-related conditions. The inclusion of an RLS-focused therapy aligns directly with that broader strategic direction, allowing the company to address a wider spectrum of sleep disorders beyond its core sleep apnea business.

Restless legs syndrome affects a significant portion of the global population and is frequently underdiagnosed and undertreated. The condition causes uncomfortable sensations in the legs, typically worsening at night, and leads to severe disruptions in sleep. By integrating Noctrix Health’s technology and clinical expertise through the acquisition of Noctrix Health, ResMed positions itself to serve patients who have not yet found effective relief through existing treatment options. The combined organization is expected to continue development efforts and pursue broader commercialization of the TOMAC platform as part of ResMed’s long-term growth strategy in sleep health.